文献速递神经肌肉病

血磷是肌萎缩侧索硬化症的独立预后因素

Phosphatemia is an Independent Prognostic Factor in Amyotrophic Lateral Sclerosis.
PubMed 文献 · Ann Neurol · 2025-04-26

研究基于PARALS队列1444例和PRO-ACT队列1023例ALS患者,评估钾、肌酐、肌酸激酶、磷、AST和ALT的诊断时血水平与生存的关联。PARALS中仅肌酐(HR=0.65,95%CI=0.50-0.85)和磷(HR=1.14,95%CI=1.04-1.24)与生存显著相关,并在PRO-ACT中验证(肌酐HR=0.21,95%CI=0.13-0.35,p<0.0001;磷HR=2.35,95%CI=1.13-4.88,p=0.02)。PRO-ACT纵向数据显示磷水平每月增加0.1 mmol/l与HR=8.26(95%CI=1.07-96.6,p=0.044)相关。

要点

  • 诊断时血磷水平与ALS生存显著相关,PARALS中HR=1.14(95%CI=1.04-1.24)。
  • PRO-ACT验证血磷HR=2.35(95%CI=1.13-4.88,p=0.02)。
  • PRO-ACT纵向数据中磷每月增0.1 mmol/l与HR=8.26相关(95%CI=1.07-96.6,p=0.044)。

核心结论

  • 肌酐血症被确认为ALS的预后标志物。
  • 诊断时血磷水平及其随时间的变化速率被确定为ALS的潜在预后标志物。
  • 血磷检测成本低且微创,支持其在临床试验中的潜在应用。

研究设计与样本

  • 研究纳入PARALS队列1444例和PRO-ACT队列1023例ALS患者。
  • 生存定义为从诊断到死亡、气管切开或删失日期的时间。
  • 对每种生物标志物构建Cox模型,并校正性别、发病年龄、发病部位和诊断延迟。
  • 在PRO-ACT数据库中评估PARALS的显著发现,并构建联合模型评估血磷斜率随时间的预后作用。

主要发现

  • PARALS队列中仅肌酐(HR=0.65,95%CI=0.50-0.85)和磷(HR=1.14,95%CI=1.04-1.24)与生存显著相关。
  • PRO-ACT队列验证肌酐HR=0.21(95%CI=0.13-0.35,p<0.0001)和磷HR=2.35(95%CI=1.13-4.88,p=0.02)。
  • PRO-ACT纵向数据显示磷水平每月增加0.1 mmol/l与HR=8.26(95%CI=1.07-96.6,p=0.044)相关。

关键数值与推荐

  • PARALS队列:肌酐HR=0.65(95%CI=0.50-0.85),磷HR=1.14(95%CI=1.04-1.24)。
  • PRO-ACT队列:肌酐HR=0.21(95%CI=0.13-0.35,p<0.0001),磷HR=2.35(95%CI=1.13-4.88,p=0.02)。
  • PRO-ACT纵向:磷水平每月增加0.1 mmol/l,HR=8.26(95%CI=1.07-96.6,p=0.044)。

临床怎么用

  • 血磷水平可在诊断时检测,作为ALS的潜在预后标志物。
  • 血磷水平随时间的变化速率可用于评估预后。
  • 血磷检测成本低且微创,支持其在临床试验中的潜在应用。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this study was to evaluate the prognostic value of several muscle damage biomarkers. METHODS: Data from Piemonte and Valle d'Aosta Amyotrophic Lateral Sclerosis (PARALS) were considered for this study. Survival was defined as the time from diagnosis to death, tracheostomy, or the censoring date. Blood levels of potassium, creatinine, creatine kinase, phosphorus, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) diagnosis were evaluated as potential prognostic biomarkers. A Cox model was developed for each biomarker and adjusted for sex, onset age, onset site, and diagnostic delay. Significant findings from PARALS were evaluated in the Pooled Resource Open-Access Amyotrophic Lateral Sclerosis Clinical Trials (PRO-ACT) database. Additionally, a joint model was constructed to evaluate the prognostic role of phosphatemia slope over time using longitudinal data from PRO-ACT. RESULTS: A total of 1,444 and 1,023 patients were included in the PARALS and PRO-ACT cohorts, respectively. Only creatinine (hazard ratio [HR] = 0.65, 95% confidence interval [CI] = 0.50-0.85) and phosphorus (HR = 1.14, 95% CI = 1.04-1.24) showed a significant association with survival in the PARALS cohort. These findings were further validated in the PRO-ACT cohort (creatinine HR = 0.21, 95% CI = 0.13-0.35, p < 0.0001; phosphorus HR = 2.35, 95% CI = 1.13-4.88, p = 0.02). Longitudinal data from the PRO-ACT database showed that an increase of 0.1 mmol/l per month in phosphate levels was also associated with a HR of 8.26 (95% CI = 1.07-96.6, p = 0.044). INTERPRETATION: Creatininemia was confirmed as a prognostic marker in amyotrophic lateral sclerosis (ALS). Additionally, both phosphatemia levels at diagnosis and its rate of change over time were identified as a potential prognostic marker for ALS. As with other blood biomarkers, phosphate levels are cost-effective and minimally invasive to measure, supporting their potential use in clinical trials. ANN NEUROL 2025;98:286-293.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Vasta R, Koumantakis E, Canosa A, et al. Phosphatemia is an Independent Prognostic Factor in Amyotrophic Lateral Sclerosis. Ann Neurol. 2025. PMID: 40285624. doi:10.1002/ana.27252

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。